Blocking the activity of the reactor called the aryl hydrocarbon receptor in T cells resulted in both a decrease in inflammation and recovery in mouse models of multiple sclerosis.
The blood level of the glial fibrillary acidic protein (GFAP) cellular component increases when astrocytes are damaged or activated. Elevated levels of GFAP in the blood can indicate both the current and future progression of multiple sclerosis.
Study reveals differences in the composition and functionality of intestinal bacteria of multiple sclerosis patients depending on whether their illness is active or whether they are in treatment.
Researchers have identified a protein that could be leveraged to help microglia in the brain stave off Alzheimer's and other neurodegenerative diseases.
Study identified three new genes that appear to be involved in the pathologies associated with multiple sclerosis.
CAR-T, a therapy generally used in the treatment of cancer, has been shown to eliminate unhealthy cells that trigger autoimmunity in mouse models of multiple-sclerosis.
80% of patients with multiple sclerosis remain disease-free for the long term following an autologous hematopoietic stem cell transplant.
The number of relapses in patients with relapsing-remitting multiple sclerosis was better controlled and symptoms of disability were stabilized or improved when patients who discontinued fingolimod changed to either ocrelizumab or natalizumab.
Diets high in guar gum, a dietary fiber and common food additive extracted from guar beans, limit inflammation and delay the onset of multiple sclerosis in mouse models.
Researchers propose a new model for Alzheimer's disease (AD2) that considers the neurodegenerative disease as an autoimmune disease that attacks the brain. Considering Alzheimer's as an autoimmune disorder could spark a new line of therapies to treat the disease.
Children who contracted COVID-19 are at increased risk of being diagnosed with Type 1 diabetes. Researchers found a 72% increase in new Type 1 diabetes cases in those under 18 who contracted COVID-19.
Researchers reveal significant differences in gut bacteria in patients with multiple sclerosis compared to those without the autoimmune disease. The study also uncovered novel mechanisms by which the bacteria may influence the disease.
